Unfortunately, in two large clinical trials with DPP4 inhibitors (Scirica, 2013; White, 2013), no significant improvements in hard cardiovascular endpoints were noted, albeit no specific analysis on the rate of AF incidence was conducted. The gene discussed is DPP4; the disease is atrial fibrillation.